Index Entries

Björn Zethelius, Sofia Attelind, Gabriel Westman, Rickard Ljung, and Anders Sundström
October 15, 2024
Vaccine: X
The Swedish Medical Products Agency (Sweden)

"Abstract

Background: During the COVID-19 vaccination campaign in Sweden, pulmonary embolism (PE) was a frequently reported suspected serious adverse drug reaction. The aim was to estimate risk of PE following vaccination for COVID-19 in the Swedish population aged 18 to 84 years ...

Results

The total population, 12–84 years old consisted of 7,513,618 individuals (49.7 % women) observed for 13,087,019 person years at risk (PYAR). Eighty percent of the study-population, 6,072,228 individuals received at least two doses of COVID-19 vaccine, i.e. the primary vaccinations scheme and 12,456 cases of PE were identified during the study period. Three percent of PE cases died within 30 days (n = 374) from PE-diagnosis."

document
adverse events,COVID-19,vaccines,vascular system issues